GI Innovation, Inc. (KOSDAQ:358570)

South Korea flag South Korea · Delayed Price · Currency is KRW
18,790
+460 (2.51%)
Aug 8, 2025, 3:30 PM KST
2.51%
Market Cap1.13T
Revenue (ttm)212.27M
Net Income (ttm)-57.20B
Shares Out61.80M
EPS (ttm)-1,288.99
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume264,801
Average Volume505,417
Open18,170
Previous Close18,330
Day's Range18,170 - 18,980
52-Week Range6,348 - 24,900
Beta0.83
RSI42.50
Earnings Daten/a

About GI Innovation

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases. The company was founded in 2017 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 358570
Full Company Profile

Financial Performance

In 2024, GI Innovation's revenue was 24.28 million, a decrease of -99.54% compared to the previous year's 5.32 billion. Losses were -58.78 billion, 5.93% more than in 2023.

Financial Statements

News

There is no news available yet.